Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
27 Feb 2026
Rare disease developers applaud clarity in FDA guidance
Stakeholders in the rare disease development community say that new guidance documents, released by the US Food and Drug Administration (FDA) over the past year, have delivered much-needed clarity on…
26 Feb 2026
Nonprofit models support strategic boldness to develop gene therapies for rare diseases
Non-profit organisations play a crucial role in supporting rare disease therapy development and rescuing shelved programmes, where commercial interest may be weak. Gene therapies represent a fundamental approach to tackling…
23 Feb 2026
Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
With the full-year 2025 earnings season coming to a close, certain sectors in healthcare performed strongly against the industry average. In the latest GlobalData Healthcare Podcast, pharmaceutical editor Robert Barrie…
17 Feb 2026
RNA-targeting small molecules: a new frontier of drug discovery
While small molecules have long been the cornerstone of the pharmaceutical industry, there is increasingly a demand for innovative precision approaches, often synonymous with biologic therapies. Yet a quiet resurgence…
16 Feb 2026
Theranostics earmarked as “the future” of radiopharmaceuticals
As the oncology market enters a new era of growth, targeted therapies across several modalities are transforming the treatment paradigm. Amid this shift, radiopharmaceuticals are emerging as a promising therapeutic…
09 Feb 2026
Pharma eyes AI deals to stem lost revenues from patent expirations
Pharmaceutical giants are employing an array of tactics to minimise the falling revenues that come when patents expire on their top drugs. Among these, experts say artificial intelligence (AI) is…